ERBB2 and cancer: ALT was found to be associated with an increased risk of death in patients with sarcoma [62], in HER2 + breast carcinoma, in angiosarcoma, pancreatic neuroendocrine tumors, liposarcoma and leiomyosarcoma but not in glioma, neuroblastoma and osteosarcoma, in which cancer types ALT + tumors had a better prognosis than TEL + tumors [58].